Holen Sie sich die Stockscreener-App
104.54
0.32%
-0.34
Handel nachbörslich:
105.00
0.46
+0.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$104.88
Offen:
$104.74
24-Stunden-Volumen:
8.07M
Relative Volume:
0.94
Marktkapitalisierung:
$132.77B
Einnahmen:
$28.75B
Nettoeinkommen (Verlust:
$480.00M
KGV:
282.54
EPS:
0.37
Netto-Cashflow:
$10.31B
1W Leistung:
+3.10%
1M Leistung:
-6.88%
6M Leistung:
+19.67%
1J Leistung:
+56.19%
1-Tages-Spanne:
$103.52
$105.75
1-Wochen-Bereich:
$100.76
$107.18
52-Wochen-Spanne:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
104.54 | 132.77B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings - MSN
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - MarketScreener
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - MarketScreener
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
News - Department of Health Abu Dhabi
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement - ZAWYA
Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell - MarketScreener
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around - The Motley Fool
Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know - MSN
Gilead Sciences CFO sells $266,000 in stock - Investing.com
Gilead Sciences CFO sells $266,000 in stock By Investing.com - Investing.com India
Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program - CSRwire
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey
Bridgewater Associates LP Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
11 Most Undervalued Quality Stocks to Buy Now - Insider Monkey
Lobbying Update: $75,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating - MarketScreener
Press Release Distribution & PR Platform - ACCESS Newswire
Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price - simplywall.st
GILD Stock Price and Chart — NASDAQ:GILD - TradingView
EPO board revives Gilead patent, sends case back for review - MLex
Gilead patent partially upheld by EPO, Teva and STADA's challenge continues - MLex
Here's What to Expect From Gilead Sciences’ Next Earnings Report - Nasdaq
Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules - Fierce Pharma
Here's What To Expect From Gilead Sciences’ Next Earnings Report - Barchart.com
Gilead Sciences, Trusaic Data Breach Lawsuit Investigation - ClassAction.org
PatientView Ranks Gilead “Best” at ESG - CSRwire
Gilead Sciences Inc (GILD) Shares Gap Down to $100.87 on Apr 10 - GuruFocus
Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025 - MarketScreener
Gilead Sciences Announces Q1 Estimated Acquired IPR&D - MarketScreener
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 | GILD Stock News - GuruFocus
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 - Business Wire
AI-startup Prezent names Gilead Sciences’ exec to Board - StartUp Beat
PatientView Ranks Gilead "Best" at ESG - MarketScreener
Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug - statnews.com
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - MarketScreener
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire - Aidsmap
Mich. Panel: Gilead Immune From Recalled COVID Drug Suit - Law360
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Gilead, Michigan Hospital Win Appeal Over Tainted Covid-19 Drug - Bloomberg Law News
Gilead Sciences (GILD) Anticipates Earnings Surprise - GuruFocus
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Gilead Sciences
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections - CSRwire
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1 - Insider Monkey
Weekly CFO Sells Highlight: Adobe Systems, Gilead Sciences and A - GuruFocus
July 18th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Sciences describes new nucleoside prodrugs for viral infections - BioWorld MedTech
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):